FDA approves t:slim X2 Insulin Pump with Dexcom G5 Mobile CGM Integration

FDA has approved the t:slim X2 Insulin Pump with Dexcom G5 Mobile continuous glucose monitoring integration. Tt:slim X2 Insulin Pump is the only touchscreen insulin pump available in the United States.t:slim X2 Insulin Pump is the first sensor-augmented insulin pump. The t:slim X2 Pump with Dexcom G5 Mobile CGM integration is approved for ages 6 and older. The t:slim X2 Pump is also the only insulin pump capable of remote software updates, allowing existing users to add features like CGM integration from home and includes advanced features like a large color touchscreen, bluetooth radio, rechargeable battery, USB connectivity, 300-unit insulin capacity and watertight construction.

Read More

FDA grants tentative approval to Sanofi’s Admelog (insulin lispro injection)

FDA has granted tentative approval to Sanofi’s Admelog (insulin lispro injection), a rapid-acting human insulin analog for improving glycemic control in adults and children with diabetes. The drug’s tentative approval is based on its similarity to its reference product, though in the United States, follow-on insulin products are not regulated as biosimilars. The originator product, Humalog, Sanofi’s insulin lispro is a rapid-acting human insulin analog is indicated to improve glycemic control in adults and children with diabetes.

Read More